Sector News

Merck inks $773M Tilos takeout to bag TGFβ cancer programs

June 11, 2019
Life sciences

Merck has struck a $773 million detail to buy Tilos Therapeutics. The takeover will give Merck control of a pipeline of cancer, fibrosis and autoimmune programs targeting the latent TGFβ complex.

Since setting up shop in 2016, Massachusetts-based Tilos has used money from Boehringer Ingelheim Venture Fund and Partners Innovation Fund to develop anti-LAP antibodies based on advances made by Galina Gabriely and Howard Weiner at Brigham and Women’s Hospital.

The focus on LAP stems from evidence that the peptide holds TGFβ, a cytokine, in an inactive form. By targeting LAP, Tilos hopes to reduce TGFβ activity. That idea caught the attention of Merck.

“Tilos has developed a compelling portfolio of candidates that employ a novel approach to modulating the potent signaling molecule TGFβ by binding to latency-associated peptide, with potential applications across a range of disease indications,” Merck Senior Vice President Dean Li said in a statement.

Tilos has focused its attention on the applications of the approach to cancer, although it also has early efforts underway in fibrosis and autoimmune disease. Neither of the companies has shared a good look at their plans for the preclinical programs, but Tilos has posted examples of how anti-LAP antibodies can work to treat disease.

Some of the anti-LAP antibodies created by Tilos are designed to deplete immunosuppressive cells and inhibit the release of TGFβ, without affecting LAB-TGFβ complexes in the extracellular matrix. In doing so, Tilos thinks it can safely inhibit pathological and immuno-regulatory processes.

Another example shared by Tilos discusses anti-LAP antibodies that preferentially bind to LAP+ myeloid-derived suppressor cells (MDSC) over LAP+ regulatory T cells. By depleting inhibitory cells, Tilos thinks it can increase antitumor activity in cancers dominated by MDSC.

Gaining the ability to manipulate the tumor microenvironment in such ways is a priority for Merck and its rivals, which are seeking drugs that make their existing immuno-oncology assets more broadly effective.

Merck could ultimately pay $773 million to buy Tilos but hasn’t disclosed what it is paying upfront.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).